Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Nektar Therapeutics (NKTR) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 1,872,230
  • Shares Outstanding, K 149,600
  • Annual Sales, $ 230,780 K
  • Annual Income, $ -81,180 K
  • 36-Month Beta 1.86
  • Price/Sales 11.19
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.75 +3.32%
on 01/23/17
13.97 -13.10%
on 01/09/17
-0.74 (-5.75%)
since 12/23/16
3-Month
11.67 +4.03%
on 12/01/16
14.74 -17.64%
on 11/14/16
-1.20 (-9.00%)
since 10/21/16
52-Week
10.52 +15.40%
on 02/24/16
19.98 -39.24%
on 09/08/16
-2.62 (-17.75%)
since 01/22/16

Most Recent Stories

More News
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday,...

Shire Gets FDA Approval for Label Expansion of Adynovate

Shire announced that the FDA has approved the use of hemophilia A drug, Adynovate,in pediatric patients under 12 years of age

Shire Announces FDA Approval of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] for use in Children and Surgical Settings

New FDA-approved indications for ADYNOVATE provides more hemophilia A patients access to proven prophylaxis with a simple, twice-weekly dosing schedule

Biotech Stocks on Investors' Radar -- Vertex Pharma, Nektar Therapeutics, CTI BioPharma, and Sage Therapeutics

In today's pre-market research, Stock-Callers.com recalls the most recent performances of four Biotech companies, namely: Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Nektar Therapeutics (NASDAQ: NKTR),...

Interesting NKTR Put And Call Options For January 2017

Investors in Nektar Therapeutics saw new options become available today, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain...

21.0% Return Seen to Date on SmarTrend Nektar Therapeutics Call (NKTR)

SmarTrend identified a Downtrend for Nektar Therapeutics (NASDAQ:NKTR) on September 27th, 2016 at $17.32. In approximately 1 month, Nektar Therapeutics has returned 21.02% as of today's recent price of...

Short Interest In Nektar Therapeutics Declines 13.3%

The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 1,253,939 share decrease in total short interest for Nektar Therapeutics , to 8,144,792, a decrease...

Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced that new Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, were presented at the SITC 2016 Annual Meeting. NKTR-214 is an investigational...

Nektar (NKTR) Stock Up on Narrower-than-Expected Q3 Loss

Nektar Therapeutics (NKTR) reported a loss of 32 cents per share in the third quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 34 cents.

Tracheobronchitis Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts - Vendors: Abbott Labs, Nektar Therapeutics, Cardeas Pharma Corp - Research and Markets

Research and Markets has announced the addition of the "Tracheobronchitis Global Clinical Trials Review, H2, 2016" clinical trials to their offering.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists...

See More

Support & Resistance

2nd Resistance Point 12.45
1st Resistance Point 12.30
Last Price 12.14
1st Support Level 11.87
2nd Support Level 11.59

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.